Ocugen: Downgrading After OCU410 Data Release

2026-03-09 15:53:34 ET

The last time I spoke about Ocugen ( OCGN ) it was with respect to a S eeking Alpha article entitled " Ocugen: Maintaining 'Buy' Rating On Positive OCU410 ST Regulatory Developments ". The reason why was because the company received alignment at that time with the FDA and EMA that a single U.S. trial would be enough to support both a Biologics License Application [BLA] and a marketing authorization application [MAA] of OCU410ST for the treatment of patients with Stargardt Disease [ST]. As an update, this program is coming along well with the pivotal phase 2/3 confirmatory study expected to have an interim data release in Q3 of 2026. This is to be followed by topline data from this study expected in Q2 of 2027....

Read the full article on Seeking Alpha

For further details see: